Severe persistent neurotoxicity associated with CAR T therapy in children

被引：1

作者：

Andrew, Eden C. ^{[1
]}

Hughes, David ^{[1
]}

Gilsenan, Maddie ^{[1
]}

Mignone, Cristina ^{[2
]}

Khaw, Seong Lin ^{[1
,3
,4
]}

Wang, Stacie Shiqi ^{[1
,3
]}

机构：

[1] Royal Childrens Hosp, Childrens Canc Ctr, Parkville, Vic 3052, Australia

[2] Royal Childrens Hosp, Med Imaging Dept, Parkville, Vic, Australia

[3] Murdoch Childrens Res Inst, Parkville, Vic, Australia

[4] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 203卷 / 04期

关键词：

CAR T-cell therapy; immune effector cell-associated neurotoxicity syndrome; immunotherapy; neurotoxicity; leukaemia; CELL THERAPY; B-CELL; TISAGENLECLEUCEL; LEUKEMIA;

D O I：

10.1111/bjh.19015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CD19-directed chimeric antigen receptor (CAR) T-cell therapy is an important therapy for relapsed or refractory acute lymphoblastic leukaemia, but its use carries the risk of immune effector cell-associated neurotoxicity syndrome (ICANS). In children, severe ICANS is almost universally reported in association with cytokine release syndrome and is reversible. We describe two cases of severe, intractable neurotoxicity following CAR T-cell therapy in children with pre-existing central nervous system (CNS) vulnerabilities. The cases were atypical in their delayed onset and independence from cytokine release syndrome and did not respond to standard therapies.

引用

页码：651 / 655

页数：5

共 50 条

[31] The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Mokhtari, Sepideh
Asquith, Justin M.
Bachmeier, Christina A.
Jain, Michael D.
Forsyth, Peter
Locke, Frederick L.
Kim, Youngchul
Lazaryan, Aleksandr
BLOOD, 2019, 134
[32] Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
Rejeski, Kai
Perez, Ariel
Iacoboni, Gloria
Blumenberg, Viktoria
Buecklein, Veit L.
Voelkl, Simon
Penack, Olaf
Albanyan, Omar
Stock, Sophia
Mueller, Fabian
Karschnia, Philipp
Petrera, Agnese
Reid, Kayla
Faramand, Rawan
Davila, Marco L.
Modi, Karnav
Dean, Erin A.
Bachmeier, Christina
von Bergwelt-Baildon, Michael
Locke, Frederick L.
Bethge, Wolfgang
Bullinger, Lars
Mackensen, Andreas
Barba, Pere
Jain, Michael D.
Subklewe, Marion
SCIENCE ADVANCES, 2023, 9 (38)
[33] Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
Nahas, George R.
Komanduri, Krishna, V
Pereira, Denise
Goodman, Mark
Jimenez, Antonio M.
Beitinjaneh, Amer
Wang, Trent P.
Lekakis, Lazaros J.
LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 940 - 943
[34] Severe Bloody Diarrhea as an Acute Complication Associated with CAR T-Cell Therapy for Refractory ALL
Shima, Haruko
Ishikawa, Takahiro
Ito, Jumpei
Keino, Dai
Kurosawa, Takumi
Yamazaki, Fumito
Goto, Hiroaki
Shimada, Hiroyuki
PEDIATRIC BLOOD & CANCER, 2020, 67
[35] DYSGRAPHIA AS THE EARLIEST PRESENTING SYMPTOM OF SEVERE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY NEUROTOXICITY: A SINGLE CENTER EXPERIENCE
Yuen, Carlen
Rezania, Kourosh
Kelly, Thomas
Bishop, Michael
NEURO-ONCOLOGY, 2021, 23 : 149 - 149
[36] Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know
Neill, Lorna
Rees, Jeremy
Roddie, Claire
PRACTICAL NEUROLOGY, 2020, 20 (04) : 287 - 295
[37] Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Zhenguang Wang
Weidong Han
Biomarker Research, 6
[38] Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
Ferreros, Puri
Trapero, Isabel
DISEASES, 2022, 10 (03)
[39] Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia
Cole, Peter D.
Kamen, Barton A.
MENTAL RETARDATION AND DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS, 2006, 12 (03): : 174 - 183
[40] CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY IN CAR-T CELL THERAPY PATIENTS
Delrosario, Maria Regina
Davison, Lisa
Schwen, Sarah
ONCOLOGY NURSING FORUM, 2019, 46 (02)

← 1 2 3 4 5 →